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Abstract
Background: This is the first study to experimentally explore the direct relationship between circulating VEGF levels and
body mass index (BMI) as well as to unravel the role of insulin sensitivity in this context under standardized glucose clamp
conditions as the methodical gold-standard. In order to control for known influencing factors such as gender, medication,
and arterial hypertension, we examined a highly homogeneous group of young male subjects. Moreover, to encompass also
subjects beyond the normal BMI range, low weight and obese participants were additionally included and stress hormones
as a main regulator of VEGF were assessed.
Methodology/Principal Findings: Under euglycemic clamp conditions, VEGF was measured in 15 normal weight (BMI 20–
25 kg/m
2), 15 low weight (BMI,20 kg/m
2), and 15 obese (BMI.30 kg/m
2) male subjects aged 18–30 years and the insulin
sensitivity index (ISI) was calculated. Since stress axis activation promotes VEGF secretion, concentrations of ACTH, cortisol,
and catecholamines were monitored. Despite of comparable ACTH (P=0.145), cortisol (P=0.840), and norepinephrine
(P=0.065) levels, VEGF concentrations differed significantly between BMI-groups (P=0.008) with higher concentrations in
obese subjects as compared to normal weight (P=0.061) and low weight subjects (P=0.002). Pearson’s correlation analysis
revealed a positive relationship between BMI and VEGF levels (r=0.407; P=0.010) but no correlation of VEGF with ISI
(r=0.224; P=0.175).
Conclusions/Significance: Our data demonstrate a positive correlation between concentrations of circulating VEGF levels
and BMI in healthy male subjects under highly controlled conditions. This relationship which is apparently disconnected
from insulin sensitivity may be part of some pathogenetic mechanisms underlying obesity and type 2 diabetes.
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Introduction
Vascular endothelial growth factor (VEGF) is a cytokine known
to increase vascular permeability and vasodilatation [1]. More-
over, there is evidence that VEGF is involved in the pathogenesis
of cancer, arteriosclerosis, obesity, and diabetes mellitus-related
complications such as diabetic retinopathy [1–3]. The synthesis
and secretion of VEGF is affected by several variables in vitro,
VEGF is up-regulated by hypoxia as well as by hyper- and
hypoglycemia [4–6]. In contrast, circulating VEGF concentrations
decrease upon hypoxia and increase upon hypoglycemia in vivo
[7–9]. Among various sides within the organism, also adipose
tissue as an endocrine organ produces VEGF in a considerable
amount [10,11]. Previous studies indicate that overweight and
obese individuals display elevated serum VEGF levels [3,12–14].
Recent data from two cross-sectional observational studies refer to
a statistical BMI dependence of VEGF levels in normal weight
subjects within a wide variance of male and female participants at
different metabolic states [15,16]. However, known influencing
factors such as fasting blood glucose levels, gender, smoking,
elevated blood lipids, or activated stress axes may influence plasma
VEGF concentrations [16,17] and have not been considered yet.
In type 2 diabetes mellitus whose pathogenesis is tightly linked to
increased body mass index [18], it has been shown that the insulin
sensitivity is decreased [19] suggesting a direct negative relation-
ship between VEGF concentrations and insulin sensitivity.
In order to further explore the indicated relationship between
plasma VEGF concentrations and BMI as well as the role of
insulin sensitivity in this context, we experimentally tested a highly
homogeneous group of young healthy male subjects under the
metabolically controlled conditions of a glucose clamp as the gold
standard to investigate insulin sensitivity [20]. Moreover, this
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Also, to additionally check if this relationship is also confirmed in
subjects beyond the normal BMI range, we included low weight
and obese subjects. We hypothesized a direct relationship between
plasma VEGF levels and body mass index (BMI) comprising all
BMI groups.
Since BMI and insulin sensitivity are known to be inversely
related [21] we moreover assumed a negative correlation between
VEGF levels and the insulin sensitivity index (ISI) which was
determined by hyperinsulinemic-euglycemic clamp technique.
Further, we monitored concentrations of catecholamines, cortisol,
and ACTH to control for the well known influence of stress
hormones on VEGF concentrations and insulin sensitivity [22–
24]. Considering the known release of VEGF by thrombocytes
[25], we measured VEGF levels in plasma samples.
Results
Glucose metabolism and insulin sensitivity
Table 1 shows main measures of the glucose clamp procedure.
The three subject groups showed no difference in fasting glucose
(P=0.304) and fasting insulin (P=0.160) levels. During the
euglycemic clamp, mean glucose levels were comparable between
groups (P=0.102). Likewise, glucose infusion rates did not differ
significantly between the three body mass groups (P=0.074). As
expected, obese subjects revealed higher insulin and c-peptide
concentrations than normal and low weight subjects (insulin
P,0.001; c-peptide P=0.002 for group comparison). M-values
(P=0.011) and ISI values (P=0.01) reflect the known negative
relationship between BMI and insulin sensitivity (Table 1).
Serum concentrations of ACTH, cortisol, and
catecholamines
Concentrations of ACTH, cortisol, and catecholamines are
summarized in Table 1. The three body mass groups did not differ
with respect to ACTH (P=0.145), norepinephrine (P=0.065), and
cortisol (P=0.840 for group comparison) concentrations. Regarding
epinephrine concentrations, we found a significant group main
effect (P=0.041) which was mainly based on lower levels in obese
participants than in normal weight controls (P=0.027). Also,
epinephrine concentrations measured in the obese subject group
were significantly lower than values of the low weight subjects
(P=0.026 for group main effect).
Plasma VEGF concentrations
Figure 1 shows VEGF concentrations in normal weight, obese
and low weight subjects under euglycemic clamp conditions.
Groups differed significantly (P=0.008 for group main effect) showing
a trend for lower VEGF concentrations in normal weight than in
obese subjects (P=0.061) and clearly higher VEGF levels in obese
as compared with low weight subjects (P=0.002). When
comparing low weight subjects with normal weight controls,
analysis failed to reach significance (P=0.156).
Notwithstanding, after merging all VEGF data of the three
subject groups, we found a clear positive correlation between
VEGF concentrations and BMI (r=0.363; P=0.017 for group main
effect; Fig. 2). In contrast to our hypothesis, however, there was no
correlation between VEGF levels and ISI (r=0.175) despite of a
clear inverse correlation between ISI and BMI (r=20.428;
P=0.007; Table 1).
Correlation analyses between VEGF levels and concentrations
of blood glucose (P=0.286), ACTH (P=0.191), cortisol (P=
0.692), epinephrine (P=0.745), norepinephrine (P=0.093), c-
peptide (P=0.167), or insulin (P=0.055) revealed non-significant
results.
Discussion
Our data demonstrate a positive correlation between plasma
VEGF concentrations and BMI over a large range of BMI between
17.6 kg/m
2 and 43.6 kg/m
2. Discrete group comparisons revealed
significantly higher concentrations of plasma VEGF in obese
subjects as compared with normal and low weight participants.
Table 1. Relevant basic characteristics of the participants, measurements of the glucose clamp procedure, and stress hormone
levels.
Category Obese subjects Normal weight subjects Low weight subjects P-value
Age (years) 27.8061.07 26.2760.96 22.5360.68 ,0.001*
Body height (m) 1.8360.18 1.8860.15 1.8060.002 0.071
Body weight (kg) 112.8163.7 77.1261.3 63.661.5 ,0.001*
BMI (kg/m
2) 33.8161.1 21.8660.3 18.9760.2 ,0.001*
Glucose (mmol/l) 5.060.1 4.860.2 5.160.1 0.102
Glucose infusion rates (ml/h) 150.6620.7 182.4619.3 123.9612.2 0.074
Insulin (mU/ml) 87.867.4 53.463.9 50.066.1 ,0.001*
C-peptide (ng/ml) 3.460.4 1.860.3 1.760.3 0.002*
M value { (mg6kg
216min
21) 7.2061.02 12.3661.35 9.3461.01 0.011*
ISI {(1006mg6l6kg
216min
216mU
21) 6.0961.09 17.8263.87 13.4361.57 0.010*
ACTH (pg/ml) 25.563.0 21.663.6 17.261.3 0.145
Cortisol (mg/ml) 10.760.8 10.760.9 10.660.7 0.840
Epinephrine(pg/ml) 20.961.7 36.265.2 39.866.5 0.041*
Norepinephrine (pg/ml) 263.4626.4 272.7625.1 199.6618.9 0.065
Indicated are mean values 6 SEM; P-values are based on ANOVA analysis.
*mark significant group differences.
{M values and ISI values were calculated as described by Eriksson et al. [32].
doi:10.1371/journal.pone.0012610.t001
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participants did not reveal a significant difference. This lacking
effect may be explained by too subtle BMI differences between the
two body mass groups which was originated from the limited
number of healthy male subjects with a BMI below 18.5 being
considered as underweight (by WHO criteria). Our findings,
however, are in line with data by Wada et al. who found by
multiple regression analyses within a group of moderately
overweight subjects with a metabolic syndrome that the indepen-
dent determinants of VEGF were the body mass index and blood
pressure [15]. Interestingly, in this study comparison of plasma
VEGF concentrations between overweight subjects with a meta-
bolic syndrome and a considerable number of normal weight
healthy controls did not reach significance which casted some doubt
on a direct relationship between circulating VEGF and BMI; a
result which can probably be explained by the inhomogeneity of the
Figure 1. Plasma VEGF concentrations during the experiment. Plasma VEGF concentrations (mean values 6 SEM) at baseline and during the
euglycemic clamp procedure. Time point 65 until time point 105 was included in the calculation of the ISI values.
doi:10.1371/journal.pone.0012610.g001
Figure 2. Correlation between plasma VEGF and BMI. Correlation of mean plasma VEGF levels (including all time points) with body mass index
by Pearson’s bivariate correlation analysis.
doi:10.1371/journal.pone.0012610.g002
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with results by Sandhofer et al. who observed in a population based
cross-sectional study comprising slightly overweight male and
female participants of different age only a weak correlation between
plasma VEGF and BMI and drew the conclusion that circulating
VEGF levels have only a minor impact on the development of
atherosclerosis [16]. In this context, it is interesting that Randeva
et al. could show in a considerable cohort of individuals that VEGF
correlates significantly with the waist-to-hip ratio [26], a measure
that, in turn, is suggested to be a better marker of subclinical
arteriosclerosis than BMI. However, also two further studies
indicated a relationship between BMI and plasma VEGF
concentrations in healthy young men and women [3,12] but did
not take into consideration that gender influences VEGF concen-
trations significantly [3]. None of these previous studies encom-
passed also obese and low weight subjects which clearly strengthens
the validity of our study. Note, since VEGF comprises a whole
family of proteins (VEGF-A-F) displaying various characteristics,
one must mention at this point that all mentioned studies in this
context determined the same specific molecule, i.e. VEGF-A, using
the same kits which allows for comparison between the studies.
Surprisingly, we did not find the assumed negative correlation
between ISI and VEGF concentrations as assessed for the first
time by standardized glucose clamp procedure although we could
confirm the well known inverse relationship between BMI and
insulin sensitivity [27]. This fact argues for a disconnection of
insulin sensitivity from the relationship between VEGF and BMI
in our study being apparently linked to other factors. In diabetic
patients, increased VEGF concentrations are assumed to be
caused by poor glycemic control [28]. In our study, we did not find
a correlation between parameters of the glucose metabolism and
VEGF levels but we could show risen serum insulin concentrations
in the obese group as compared with the other groups which may,
on the long term, lead to glycemic dysregulation. The influence of
insulin per se on plasma VEGF, however, is not clarified yet.
Dandona et al. [29] found a suppression of VEGF levels due to
high insulin concentrations in obese subjects, a result that contrasts
to our data rather indicating a relationship between high insulin
levels and increased circulating VEGF concentrations. Notwith-
standing, the influence of insulin on circulating VEGF still remains
to be further clarified. ISI values, however, are regarded as a
valuable tool to investigate insulin resistance. In the obese men of
our study, ISI values were low and insulin concentrations were
increased confirming insulin resistance as a well known phenom-
enon in overweight subjects. Whatsoever, there was no indication
for an association between ISI and plasma VEGF in our study.
When trying to explain the underlying causes why VEGF
concentrations correlate with BMI, some confounding factors need
to be considered. In order to exclude the known bias of activated
stress hormonal systems, we concomitantly monitored circulating
concentrations of catecholamines as well as ACTH and cortisol.
Our data, however, do not confirm the assumed influence of stress
hormones on VEGF levels. Neither BMI group comparisons nor
correlation analyses with VEGF concentrations revealed signifi-
cant effects of ACTH and cortisol in contrast to previous findings
[30]. In foregoing studies, it has been shown that also
catecholamines influence VEGF levels by inducing VEGF
expression [31]. Our catecholamine measurements are not in line
with these data because we did not find a correlation between
VEGF and catecholamine concentrations. Moreover, our norepi-
nephrine levels showed no differences between groups and
epinephrine levels were even lower in obese subjects than in the
other BMI groups. Thus, catecholamines do not appear to be
involved in mediating the relationship between VEGF levels and
BMI. Another potential confounder in our study may be age [16].
Our low weight subjects were significantly younger than normal
weight and obese subjects. Notwithstanding, the age difference
between normal weight and obese subjects did not reach
significance and previous studies do not find any age related
effects on plasma VEGF levels [3,14]. Also, the narrow range of
age in our study varying between 18 years and 30 years does not
argue for age as an underlying factor of VEGF differences.
In summary, we have shown a positive correlation between
circulating VEGF levels and body mass index which is independent
of insulin sensitivity. Since the underlying mechanisms of these
coherences and the role of VEGF in the pathogenesis of obesity
currently remain unclear, further studies possibly also involving
animal and in vitro approaches are desirable to answer open
questions. Our results suggest that an obesity-associated VEGF rise
could play a majorrole inthedevelopmentofknown type 2 diabetes
related sequelae like diabetic retinopathie. Body weight may thus be
a factor which is even more relevant in this context than the
disturbed glucose metabolism itself.
Methods
Subjects
Three groups comprising 15 normal weight (BMI 20–25 kg/
m
2), 15 low weight (BMI,20 kg/m
2), and 15 obese (BMI.30 kg/
m
2) male subjects aged 18–30 years were included. Relevant main
characteristics are shown in Table 1. Exclusion criteria were acute
or chronic illness incl. arterial hypertension, alcohol or drug abuse,
smoking, competitive sports, shift work, exceptional physical or
mental stress, and any kind of current medication. On the day
preceding the tests, all subjects were requested to abstain from
alcohol, not to perform any kind of exhausting physical activity,
and to go to bed no later than 11:00 p.m. Each participant gave
written informed consent and the study was approved by the ethics
committee at the University of Luebeck.
Experimental design
On the day of the experiment, subjects arrived at the medical
research unit at 08:00 a.m. after an overnight fast of at least
12 hours. One cannula was inserted into a peripheral vein of the
arm, while the second one was inserted into an antecubital vein of
the contralateral arm. The first blood sample was taken at 8:30
a.m. to determine baseline concentrations of VEGF, ACTH,
cortisol, insulin, c-peptide, glucose, and catecholamines. After this
baseline period, an insulin bolus (H-insulin, Hoechst, Frankfurt,
Germany) was infused with a rate of 5 mU6min
216kg
21 for
2 min followed by a continuous infusion rate of 1.5 mU6
min
216kg
21 for the next 100 min. A 20% dextrose solution was
infused simultaneously at a variable rate to maintain a euglycemic
plasma glucose level of 5.5 mmol/l. This euglycemic plateau was
stable after 55 minutes of insulin infusion and maintained for
another 45 minutes. Blood glucose concentrations were monitored
at 5 min intervals during the experiments (B-Glucose-Data-
Management, HemoCue GmbH, Grossostheim, Germany). Hor-
monal blood samples were drawn every 10 minutes throughout
the experiment.
Blood was centrifuged within 5 min after withdrawal and serum
as well as plasma was kept at 272uC until assay. At 10:20 a.m.,
infusion of insulin was stopped and the euglycemic state was
reached after 30 minutes of glucose infusion.
Assays
PlasmaVEGFA samplesweremeasuredbyELISA(VEGFinter-
assay coefficient of variation ,8.8%, intra-assay CV 6.7%; R&D
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ACTH, cortisol, c-peptide, and insulin concentrations were
measured by commercial enzyme-linked immunoassays (all Im-
mulite, DPC, Los Angeles, USA) with the following intra-assay and
inter-assay coefficients of variation respectively: cortisol ,5.8%
and ,6.3%, c-peptide ,7.6% and ,10.5%, insulin ,5.2% and
,6.1%, ACTH ,6.1% and ,9.4%. Plasma epinephrine and
norepinephrine concentrations were measured by standard high-
performance liquid chromatography with electrochemical detection
(Recipe Chemicals+Instruments, Munich, Germany) with the
following intra-assay and inter-assay coefficients of variation,
respectively: epinephrine ,7.6% and ,4.2%, norepinephrine
,6.7% and ,5.3%.
Statistical analysis
Values are presented as mean values 6 standard error of mean
(SEM). Statistical analyses were based on analysis of variance for
repeated measurements (ANOVA) with the factors ‘‘time’’ (11 or 5
time points in case of catecholamine determination) and ‘‘group’’
(normal, obese, low weight subjects), followed by post hoc t-tests
for pair wise comparisons. ISI was calculated as described by
Eriksson et al. [32] and P-values were charged by oneway
ANOVA. Correlations were performed by bivariate correlation
analysis according to Pearson. A P-value,0.05 was considered
significant.
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